GUANAZOLO IN THE THERAPY OF HODGKIN’S DISEASE

Abstract

Five patients with active Hodgkin’s disease were treated for a period varying from four to eighteen days with an antiguanine preparation, guanazolo (5-amino-7-hydroxy-1H-v-triazolo[d]pyrimidine) with a total dosage of 400 mg. to 800 mg. intramuscularly. No therapeutic effect was observed. The only toxic manifestations were pain and tenderness at the site of injection in 4 of the 5 cases. The effect of guanazolo on tissue cultures of an involved node was tested. No inhibition of growth was observed, thus paralleling the lack of in vivo effect.